Step Up for Success: Navigating Bispecific Antibody Care Across Practice Settings in Multiple Myeloma
Webinar/Online
Wednesday, January 21, 2026 at 2:00pm ET - 2:45pm ET
Add this event to your calendar
Info
Topic
Join us for a live webinar where multiple myeloma (MM) experts will address real-world challenges and solutions for integrating bispecific antibodies (bsAbs) into community oncology practice. Leveraging key data and insights stemming from an innovative Hub and Spoke education model between academic and community oncology practices, faculty will discuss strategies for optimizing step-up dosing, adverse event management, and clinic referral and transition of care workflows. Additionally, utilizing the Bispecific Antibody Care Transitions to Community Practice Playbook developed specifically for this program, faculty will walk attendees through this resource, providing best practices for administering and co-managing patients receiving bispecific antibodies in your setting. Don't miss this opportunity to enhance your knowledge, ask top-of-mind questions, and harness new approaches to optimize MM care with bispecific antibodies.
Credits Offered
This event offers
0.75 contact hours
to attendees.
Accreditation Info:
AANP.
Additional Information
Join us for a live webinar where multiple myeloma (MM) experts will address real-world challenges and solutions for integrating bispecific antibodies (bsAbs) into community oncology practice.
Speakers
Assistant Professor
Division of Myeloma
Department of Hematology and HCT
City of Hope National Medical Center
Scott Goldsmith, MD is an Assistant Professor in the Multiple Myeloma Division at City of Hope Comprehensive Cancer Center (COHCCC) in Duarte, California. He received in Medical Doctorate from the University of Florida, and subsequently completed his Internal Medicine residency and chief residency, and Hematology/Oncology fellowship at the Washington University School of Medicine in St. Louis, Missouri. He joined the faculty in the Department of Hematology and Hematopoietic Cell Transplantation at COHCCC in 2021. Clinically, he focuses exclusively on treating patients with multiple myeloma and other plasma cell dyscrasias with experience and expertise with all treatment modalities, especially cellular and immunotherapies. His clinical and translational research focuses include combining radiotherapies with myeloma immunotherapies, understanding and mitigating toxicities of cellular therapies, and peripheral blood minimal residual disease assessments, and he is supported by several institutional and foundational grants.
Associate Professor of Medicine
Division of Hematology/Medical Oncology, School of Medicine
Oregon Health & Science University
Portland, OR
Dr. Silbermann cares for patients with multiple myeloma and other plasma cell disorders including AL amyloidosis and POEMS at Oregon Health & Science University, where she leads the multiple myeloma program and is an Associate Professor of Medicine. She is particularly interested in myeloma bone disease and preservation of function in elderly myeloma patients. Her clinical research program focuses on novel drug targets and drug combinations for patients with relapsed and refractory multiple myeloma. She completed her hematology and medical oncology training at the University of Pittsburgh and previously served on the faculty at the University of Pittsburgh and Indiana University before moving to OHSU in 2017.